News & Updates

Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates

In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.

ACOG article 2.4

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Double whammy: Depression and IBD increase hospital readmission, death

Individuals with comorbid depression and inflammatory bowel disease (IBD) are at increased risks for hospital readmission and mortality at 30 days after readmission as shown in a retrospective observational study presented at CCC 2024.

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Ocular complications develop in RA, connective tissue disease, vasculitis patients

Nearly one-fifth of patients with rheumatoid arthritis (RA) develop ocular complications, as do one-quarter to one-third of those with connective tissue diseases and vasculitis, according to a recent study.

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

Use of cycline antibiotics (CAs) is associated with an elevated risk of pseudotumour cerebri syndrome (PTCS) or papilledema, suggests a recent study. However, no statistically significant link between CA use and PTCS development is seen when accounting for confounding factors.